Nonathymulin
Also known as: FTS analog, Thymulin analog, Zn-thymulin analog, ZnT
Summary
Nonathymulin (also called Zn-thymulin analog or ZnT) is a synthetic nonapeptide analog of thymulin, a naturally occurring thymic hormone. It retains the zinc-binding and immunomodulatory properties of the native peptide. Research has explored its roles in immune reconstitution, neuroprotection, hair follicle cycling, and anti-inflammatory activity. It is not approved for clinical use and remains an investigational/research compound.
Mechanism of Action
Synthetic analog of facteur thymique sérique (FTS/thymulin); binds zinc to form the biologically active zinc-thymulin complex; modulates T-cell differentiation and maturation, promotes T-lymphocyte functional activity, and exhibits anti-inflammatory and neuroprotective effects via modulation of cytokine production and HPA axis interactions
Routes of Administration
Goals & Uses
- NeuroprotectionNeurologyLow
- Immune reconstitution / T-cell modulationImmunologyLow
- Immunosenescence reversalAging / GeroscienceLow
- Hair follicle cycling / alopeciaDermatologyLow
- Anti-inflammatory effectsInflammationLow
Contraindications
- Known hypersensitivity to thymic peptidesAllergic/ImmunologicalHigh
- Active autoimmune diseaseAutoimmunityModerate
Adverse Effects
- Immune dysregulationImmunologicalUnknown
- Injection site reactionsLocalUnknown
Drug Interactions
- Immunosuppressants (e.g., corticosteroids, calcineurin inhibitors)Moderate
- Zinc supplementsLow
Population Constraints
- Patients with active malignancyOncologyRelative
- Pediatric populationAgeRelative
- Pregnant or lactating womenReproductiveRelative
Regulatory Status
- European UnionUnapprovedNot approved by EMA; preclinical research compound
- United StatesUnapprovedResearch compound only; no FDA approval or IND on public record
- United KingdomUnapprovedNot approved by MHRA; research use only
Not approved by FDA, EMA, or any major regulatory agency. Used exclusively in preclinical and early research settings. No IND or clinical trial approvals identified in public databases.
Evidence & Sources
No sources recorded yet.